12/18/2023 0 Comments Ancora heart“The core values of the Ancora team, which are focused on helping patients live healthier lives, align strongly with my own. ![]() “Ancora Heart is at a very exciting point in its growth pathway, and I am excited to be joining the team at this stage,” said Tucker. David’s expertise in financial planning, operations, and fundraising for organizations pioneering novel therapeutics make him an excellent person to have at the helm of our finance function during this next phase of growth.”Ī fundamentally different and innovative device-based therapy, the AccuCinch System is designed to improve the structure and function of the heart and help bring relief to patients with heart failure who remain symptomatic despite current guideline-directed medical care. “While our current clinical focus is on the CORCINCH-HF pivotal trial, we are also looking toward the future, which includes a goal of eventual commercialization. “David’s experience includes providing financial leadership across a broad spectrum of companies at a variety of stages, including both public and private life sciences organizations, and we are thrilled to have him join our team,” said Jeff Closs, president and CEO of Ancora Heart. Circulation 2017 135: pp.This press release features multimedia. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Benjamin E.J., Blaha M.J., Chiuve S.E., et al. Current heart failure treatments only partially address the enlarged left ventricle and up to 50 percent of people who develop heart failure die within five years of diagnosis.1ġ. About half of heart failure patients have an enlarged left ventricle, the main pumping chamber of the heart, which causes more stress on the heart and leads to reduced pumping efficiency. ![]() The AccuCinch system is designed to directly repair the left ventricle of the heart, thereby addressing the fundamental issue in the progression of systolic heart failure.Īn estimated 25 million adults worldwide live with heart failure, a condition in which the heart’s muscles slowly weaken and lose their ability to pump enough oxygen-rich blood to the body.1 Heart failure patients suffer from debilitating symptoms including persistent exhaustion, trouble breathing, confusion and loss of memory. ![]() For patients where heart failure has progressed beyond the ability for medications and pacemakers to manage symptoms, non-surgical percutaneous device therapy with AccuCinch may provide an effective treatment option. For some patients, AccuCinch may have the potential to reverse the enlargement of the left ventricle. The transcatheter AccuCinch therapy is designed to complement and enhance the existing care cardiologists provide to further manage symptoms and slow, or stop, the progression of heart failure. The study will enroll up to 132 patients from heart centers across Europe. This is the second recently initiated Ancora study evaluating the AccuCinch system focused specifically on heart failure and the enlarged left ventricle. “We are pleased to participate in this study because the AccuCinch has the potential to address the shortcomings of current medical, surgical and transcatheter treatments and restore quality of life and longevity for this large patient population.” “The transcatheter AccuCinch therapy is unique in its ventricular approach, which is intended to improve heart function by repairing the left ventricle for patients with systolic heart failure regardless of its origin,” said Neužil. The AccuCinch procedure was completed by co-investigator Vivek Reddy, M.D., director of cardiac arrhythmia services at The Mount Sinai Hospital in New York, along with Neužil. Petr Neužil, M.D., CSc., FESC, head of the department of cardiology at Homolka Hospital and principal investigator of the study. The first patient was enrolled at Homolka Hospital in Prague, Czech Republic by Prof. announced the first patient was enrolled in the CorCinch EU study, a European multi-center clinical evaluation of the AccuCinch Ventricular Repair System as a treatment for patients with reduced ejection fraction systolic heart failure (HFrEF). ![]() Study will evaluate percutaneous therapy designed to improve left ventricular function for patients with systolic heart failureĪugAncora Heart Inc. 原标题:Ancora Heart Enrolls First Patient for AccuCinch Heart FailureĪncora Heart Enrolls First Patient in European Multi-center Study of AccuCinch Heart Failure Therapy
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |